Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10182242 | 0.94 | KDR (0.38) | KDRPDGFRBCNR1CNR2BRAF | |
| SCHEMBL869955 | 0.91 | LMNA (0.38) | KDRPDGFRBBRAFKMT2AMAPK1 | |
| SCHEMBL10182239 | 0.89 | KDR (0.36) | KDRPDGFRBCNR1CNR2BRAF | |
| SCHEMBL869137 | 0.88 | BRAF (0.37) | KDRPDGFRBBRAFKMT2AMAPK1 | |
| SCHEMBL848443 | 0.87 | KDR (0.60) | KDRPDGFRB | |
| SCHEMBL10183241 | 0.87 | MAPK1 (0.36) | KDRPDGFRBCNR1CNR2BRAF | |
| SCHEMBL871802 | 0.87 | KMT2A (0.42) | KDRPDGFRBBRAFKMT2AMAPK1 | |
| SCHEMBL872934 | 0.86 | KDR (0.41) | KDRPDGFRBBRAFKMT2AMAPK1 | |
| SCHEMBL10183863 | 0.86 | KDR (0.35) | KDRPDGFRBBRAFKMT2AMAPK1 | |
| SCHEMBL872089 | 0.85 | KMT2A (0.36) | KDRPDGFRBBRAFF10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383825-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120207810-A1 | Kinase Inhibitors | SPADA LON T (US) | 2012-08-16 | — | — | US | disclosed |
| US-8143410-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110263611-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20090196906-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263611-A1 | Kinase Inhibitors | PTK2, MAP3K6, MAP3K20 | KDR 51/4885PDGFRB 368/4885CNR1 2846/4885 |
| US-20120207810-A1 | Kinase Inhibitors | PTK2, MAP3K6, MAP3K20 | KDR 51/4885PDGFRB 368/4885CNR1 2846/4885 |
| US-20090196906-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | KDR 51/4885PDGFRB 368/4885CNR1 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.